Twenty state attorneys general sued a group of generic drug companies Thursday, accusing them of conspiring to fix prices on an antibiotic and a diabetes medication.
The suit comes a day after price-fixing charges against former executives at one of the drugmakers were unsealed in a Justice Department antitrust probe.
The attorneys general, including New York’s Eric Schneiderman and Connecticut’s George Jepsen, alleged in a suit filed in Connecticut federal court that Heritage Pharmaceuticals; Aurobindo Pharma USA; Citron Pharma; Mayne Pharma; Mylan Pharmaceuticals; and Teva Pharmaceuticals USA, conspired to manipulate prices for doxycycline hyclate, an antibiotic, and glyburide, used in the treatment of diabetes.
On Wednesday, federal prosecutors unsealed charges against Heritage’s former chief executive and former president, alleging they conspired with competitors to fix prices and allocate customers for the same two drugs.
Heritage has said it fired those executives and is cooperating with the Justice Department.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI